Novo Nordisk has filed for FDA approval of a higher-dose Wegovy injection, backed by strong trial data and a national priority voucher.
Pharma giant Novo Nordisk has filed for US approval of a higher-dose version of Wegovy, its blockbuster obesity drug. The company has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for a 7.2 mg, once-weekly semaglutide injection – nearly triple the current 2.4 mg dose.
The application is being fast-tracked under the FDA’s new Commissioner’s National Priority Voucher (CNPV) program, allowing a decision in as little as one to two months [1]. A process that typically takes 10–12 months could now take weeks.
The higher dose of Wegovy is intended for chronic weight management in adults with obesity, alongside a reduced-calorie diet and increased physical activity. Novo Nordisk says the new formulation could offer “greater weight loss potential,” a claim supported by the company’s 72-week, phase 3 STEP UP trial [2].
“
The trial enrolled 1,407 adults with obesity but without diabetes. From a starting weight of 249 pounds on average, participants taking the 7.2 mg dose lost 20.7% of their body weight after 72 weeks – compared with 17.5% in the 2.4 mg group and 2.4% with placebo. Around one-third of people on the higher dose lost 25% or more of their body weight.
To put it simply, for someone weighing 100 kg, a 20% weight reduction is the equivalent of losing 20 kg, roughly the weight of a small suitcase.
As expected with GLP-1 drugs, gastrointestinal side effects were more common at the higher dose. But rates of serious adverse events were lower with the 7.2 mg (6.8%) than with the 2.4 mg dose (10.9%), though slightly higher than with placebo.
Novo Nordisk’s application is one of the first to use the newly introduced CNPV program, a mechanism designed to accelerate regulatory review for “select products” where companies commit to affordability plans, domestic manufacturing, or areas of significant unmet need. Wegovy was among the first 15 drugs named under the program.
Under CNPV, review teams conduct a one-day, multidisciplinary assessment – much faster than the standard or even priority review pathways.
Despite controversies that the scheme could favor politically connected drugmakers or lead to rushed decisions [3], the FDA maintains that approval standards remain unchanged and that the program incentivizes innovation in areas where it has historically lagged.
In the field of longevity, the implications are noteworthy. Obesity is one of the most significant modifiable drivers of accelerated aging, linked to metabolic dysfunction, inflammation, cardiovascular disease and reduced healthspan. Treatments that can reliably reduce body weight by 15–25% have the potential to shift population-level health trajectories.
Higher-dose semaglutide may:
- Lower the burden of metabolic aging by reducing visceral fat and chronic inflammation
- Improve cardiovascular healthspan, especially as GLP-1 drugs have shown heart-protective effects [4]
- Enhance mobility and reduce age-related joint strain
- Delay onset of chronic diseases across midlife
However, the longevity community remains divided. Some experts argue that GLP-1 drugs address symptoms – not root causes – of metabolic aging. Others believe they represent one of the most impactful tools currently available, particularly at a population scale.
The move toward higher doses, wider access, and eventual oral formulations (“Wegovy in a pill”) suggests that GLP-1s will continue shaping the landscape of preventive and longevity medicine for years to come [5].
The 7.2 mg formulation is already under review in the UK, Europe and several other regions, with an EU decision expected in the first quarter of 2026. If the FDA approves the higher dose within the expedited window, Novo Nordisk could see multiple major regulatory wins before year-end, including a decision on its 25 mg oral semaglutide.
For a drug class that has set off a global scramble – from biotech startups to food manufacturers – the stakes around semaglutide’s next chapter are high.
As demand for weight-loss treatments continues to surge, the question is no longer whether GLP-1 drugs will reshape obesity care, but how quickly, and at what scale.
Photograph: Rebel Red Runner/ShutterStock
[1] https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program
[2] https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916464
[3] https://democrats-energycommerce.house.gov/sites/evo-subsites/democrats-energycommerce.house.gov/files/evo-media-document/11.20.25-final-letter-to-fda-on-cnpv.pdf
[4] https://academic.oup.com/ehjcvp/article/11/6/552/8172530
[5] https://www.sciencedaily.com/releases/2025/11/251106003913.htm
